

dexcomG6

ZERO
FINGERSTICKS*
OR SCANNING

EMPOWER YOUR PATIENTS WITH DEXCOM G6.

Dexcom Continuous Glucose Monitoring (CGM) System use is clinically proven to reduce HbA1c, reduce hypoglycemia, and increase time in range.^{1,2}



Smart devices sold separately.†

HOW DOES THE DEXCOM G6 WORK?



APPLICATOR

- Simple auto-applicator to insert the sensor just beneath the skin



SENSOR

- Measures glucose levels for up to ten days
- Accurate glucose readings even when taking paracetamol³



TRANSMITTER

- Snaps into the top of sensor
- Sends data wirelessly to a display device[†]
- 3-month battery life



DISPLAY DEVICE

- Dexcom receiver or compatible smart device[†]




WHAT IS CONTINUOUS GLUCOSE MONITORING?

Continuous glucose monitoring (CGM) systems are diabetes management tools that measure glucose at regular intervals using a sensor inserted just under the skin. The device wirelessly transmits glucose readings to a compatible smartphone, smart watch or receiver.[†] It provides patients with real-time glucose readings but can also alert them when their levels rise too high or drop too low, helping your patients stay in range.

WHO CAN BENEFIT FROM CGM USE?

- Patients with type 1 diabetes (T1D), from 2 years old, including pregnant women
- Patients on Multiple Daily Injections (MDI) insulin therapy or using an insulin pump

Natalie,
Dexcom Warrior,
living with T1D
since 2007.



Other considerations for patient selection:

- Impaired awareness of hypos or > one severe hypo per year
- Not at HbA1c goal
- Has hypoglycaemia unawareness
- Has glycaemic variability
- Has hyperglycaemia due to fear of hypoglycaemia



Smart devices sold separately.[†]

DEXCOM CGM FIRST. WHEN PERFORMANCE MATTERS.



REAL-TIME READINGS

With just a quick glance at a smart device, your patients can see where their glucose levels are heading and how fast so they can take action.




EXCEPTIONAL ACCURACY⁴

Dexcom G6 is the first CGM device to meet the FDA iCGM special controls on accuracy, reliability and clinical relevance.⁵



ZERO FINGERSTICKS* OR SCANNING

The Dexcom G6 provides the freedom to manage diabetes without calibrations and with zero fingersticks,* even for diabetes treatment decisions.



HIGH AND LOW ALERTS

With the Dexcom G6, patients have the power to customise alerts so they can know when they're high or low with a quick glance at their smart device.[†]



URGENT LOW SOON ALERT

At times, glucose levels fall quickly. A predictive Urgent Low Soon alert can warn you up to 20 minutes in advance of severe hypoglycaemia (≤ 3.1 mmol/L).




INTEROPERABILITY

Dexcom is leading the way for your patients with T1D with integration in multiple Closed-Loop Automated Insulin Delivery systems.



SHARE GLUCOSE DATA

With Dexcom Share, patients can share their Dexcom G6 glucose data with up to 5 followers.[‡]



DEXCOM CLARITY

Keep track of your patients' CGM trends with Dexcom CLARITY and help them better manage their diabetes.

* If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

PROVEN CLINICAL OUTCOMES WITH DEXCOM CGM.

Dexcom CGM use has proven to:^{1,2}



Increase time in range^{1,2}



Reduce HbA1c^{1,2}



Reduce risk
of hypoglycaemia⁶



Improve quality
of life and well-being⁷

DEXCOM G6 LEADS THE WAY FOR YOUR T1 PATIENTS

dexcom.com/UKIEHCP

Christian and his son Ethan,
Dexcom Warrior,
living with T1D since 2016.



dexcomG6

Smart devices sold separately.[†]

^{*}If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. [†]For a list of compatible devices, visit www.dexcom.com/compatibility. [‡]Internet connectivity required for data sharing. Following requires the use of the Follow App. Followers should always confirm readings on the Dexcom G6 App or receiver before making treatment decisions. 1 Beck RW, *et al.* JAMA. 2017;317(4):371-378. 2 Welsh JB, *et al.* Diabetes Technol Ther. 2019;21(3):128-132. 3 Calhoun P, *et al.* J Diabetes Sci Technol. 2018;12(2):393-396. 4 Shah VN, *et al.* Diabetes Technol Ther. 2018;20(6):428-433. 5 Approval Letter for DEN170088: Dexcom G6 Integrated Continuous Glucose Monitoring System. Food & Drug Administration, Division of Chemistry and Toxicology Devices, 2018. 6 Heinemann L *et al.* Lancet 2018;391(10128):1367-77. 7 Polonsky WH *et al.* Diabetes Care 2017;40(6):736-41. Dexcom, Dexcom G6, Dexcom Follow, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the U.S. and may be in other countries. © 2020 Dexcom International Ltd. All rights reserved. Dexcom International Ltd and its affiliated European entities. This product is covered by U.S. patent. www.Dexcom.com | +1.858.200.0200 | Dexcom, Inc. 6340 Sequence Drive San Diego, CA 92121 USA | MDSS GmbH Schiffgraben 41 30175 Hannover, Germany. LBL018884 Rev002.